On Mar. 23, 2026, Wilmington PharmaTech, a leading U.S.-based research, development, and manufacturing organization (CRDMO) focused on complex custom small-molecule API production, announced a $50 million expansion of its Delaware campus to more than double its current API reactor capacity, supporting growing demand for high-quality, U.S.-based manufacturing.

The expansion will add two new 10,000-liter reactor suites, significantly increasing Wilmington’s commercial‑scale manufacturing capabilities and enhancing the company’s ability to support large‑scale production of small molecule APIs and peptides. The new suites are expected to come online in the third quarter of 2027. Upon completion, the company expects to approximately double its site workforce.

This investment represents the second phase of Wilmington’s multi-year strategy to expand domestic API manufacturing capacity. It builds on the company’s recent addition of dedicated suites for the manufacture of highly potent API (HPAPI). Together, these investments further position Wilmington as a preferred U.S.‑based partner for biopharmaceutical innovators seeking secure domestic supply.